UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 22, 2019
Progenics Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-23143 |
|
13-3379479 |
|
(State or other jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
|
One World Trade Center, 47th Floor, New York, New York 10007 |
||||
|
(Address of Principal Executive Offices) (Zip Code) |
||||
|
|
|
|
|
|
|
Registrant’s telephone number, including area code: (646) 975-2500 |
||||
|
|
||||
|
Not Applicable |
||||
|
(Former name or former address, if changed since last report) |
||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☒ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On April 22, 2019, Progenics Pharmaceuticals, Inc. (the “Company”) delivered a letter (the “Response Letter”) to Velan Capital, L.P. (“Velan”) in response to the Notice of Director Nominations the Company received from Velan, dated March 15, 2019. A copy of the Response Letter is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference.
Item 9.01. Financial Statements and Exhibits.
d) Exhibits.
|
Exhibit No. |
Description |
|
|
99.1 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
PROGENICS PHARMACEUTICALS, INC. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Patrick Fabbio |
|
|
|
|
Patrick Fabbio |
|
|
|
|
Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) |
|
Date: April 22, 2019